The CMR GUIDE trial didn’t meet its primary endpoint but did point to possible positives, especially in younger patients.

The US Food and Drug Administration has granted an expanded indication to tirzepatide (Mounjaro) for reducing major adverse ...

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

Because of the low number of events in the trial, the findings are thought-provoking but not definitive, one expert says.

Compared with standard treatment, an abbreviated regimen was associated with more relapses but didn’t compromise safety.